MiniMed Group (NASDAQ:MMED) Price Target Raised to $28.00

MiniMed Group (NASDAQ:MMED) had its price objective upped by UBS Group from $25.00 to $28.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms also recently commented on MMED. Mizuho lifted their target price on shares of MiniMed Group from $21.00 to $26.00 and gave the stock an “outperform” rating in a research report on Wednesday. Benchmark reissued a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th. BTIG Research raised their price target on MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday. Bank of America lifted their price objective on MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wells Fargo & Company lowered their target price on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.77.

MiniMed Group Price Performance

Shares of MMED stock opened at $23.28 on Wednesday. The business has a 50 day moving average of $18.21. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $24.43. The company has a market capitalization of $6.55 billion and a price-to-earnings ratio of -34.24.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The company had revenue of $837.00 million for the quarter. The company’s quarterly revenue was up 15.6% on a year-over-year basis. Sell-side analysts forecast that MiniMed Group will post 0.7 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. J. Goldman & Co LP purchased a new position in shares of MiniMed Group during the 2nd quarter worth $12,412,000. Freestone Grove Partners LP purchased a new stake in shares of MiniMed Group in the 2nd quarter worth $1,745,000. Deutsche Bank AG bought a new position in MiniMed Group in the 2nd quarter worth $420,000. BlackRock Inc. raised its holdings in MiniMed Group by 7,527.5% in the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock worth $29,848,000 after purchasing an additional 1,970,314 shares during the period. Finally, Punch & Associates Investment Management Inc. purchased a new position in MiniMed Group during the second quarter valued at $292,000.

Key MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.